TempraMed Technologies Ltd.

Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement.Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year...

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med™ to the distribution framework, and supports broader regional availability following product registrations Highlights •          TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.•          The amended framework adds VIVI...

Toronto, ON – Sept 23, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the “Distribution Agreement”) with...

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025 Toronto, ON – Sept 18, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) (“TempraMed” or the “Company”), a medical-technology innovator...

Acceptance of TempraMed’s products by Meuhedet Health Services strengthens TempraMed's B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally Highlights -          Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™...

Highlights -          TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading-          Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications-          LOI includes minimum annual purchase commitments in Year 1-          Expands TempraMed’s footprint across the Middle East and supports broader regional...

Integration into McKesson’s Medical-Surgical Solutions marketplace serving a nationwide customer base Toronto, ON – June 30, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical (“MMS”). The agreement, dated...

Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets Highlights -          Granted Patent covers the design of VIVI Cap Smart across major international, growing market-          Strengthens the Company’s intellectual property position in one of the world’s largest healthcare and consumer markets-          Supports commercialization...

Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, BC - February 10, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super‑Pharm, Israel’s largest and...

Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members Vancouver, BC – February 6, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed...

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed’s full product portfolio  Vancouver, BC – February 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator...

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channels Highlights -          Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature-          Designed for medications...